Portal de Periódicos da CAPES

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

2021; eLife Sciences Publications Ltd; Volume: 10; Linguagem: Inglês

10.7554/elife.68808

2050-084X

Nick K Jones, Lucy Rivett, Shaun R. Seaman, Richard J. Samworth, Ben Warne, Christopher T. Workman, Mark Ferris, Jo Wright, Natalie Quinnell, Ashley Shaw, Amy Amory, Stephen Baker, Emma Bateman, Aklima Begum, Moushima Begum, John R. Bradley, Michael Brennan, Helen Burn, Caroline Crofts, Afzal Chaudhry, Yasmin Chaudhry, Daniel J Cooper, S. Dawson, Gordon Dougan, Renny Feather, Louise Free, Katie Friel, Claire Gildea, Iliana Georgana, Lizz Grimwade, Ravi Gupta, Susan Hall, Sophie Hannan, James Hayes, Aleksandra Hosaja, Myra Hosmillo, Rhys Izuagbe, Aminu S. Jahun, Lidia James, Jill Jardin, Nathalie Kingston, Sara Lear, Paul Lyons, Patrick H. Maxwell, Sue Mott, Sarah Mugavin, Joyce Mwiya, Sharon Peacock, Ravi Prakash Nallattil, Kazeem Oloyede, Willem H. Ouwehand, Elle Page, Marina Sanchez Perez, Tim Raine, Matthew Routledge, Caroline Saunders, Kenneth G. C. Smith, Dominic Sparkes, Maria Stafford, Charlotte Summers, Despiona Tatsi, James Thaventhiran, Sharon Johnson, M. Estée Török, Mark Toshner, Lesley Turner, Kate Wall, Karis Watson, Ian Goodfellow, Paul J. Lehner, Rob Howes, Giles Wright, Nicholas J. Matheson, Michael P. Weekes,

Vaccine Coverage and Hesitancy

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission , as well as the burden of COVID-19 disease .